|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2008-2-18
|
|
pubmed:abstractText |
Malignant rhabdoid tumor (MRT) is an early childhood cancer with poor prognosis. Trastuzumab, a humanized monoclonal antibody against human epidermal growth factor receptor-2 (HER-2), has been shown to be effective against breast cancer and other cancers. We investigated the effect of trastuzumab on MRT cell lines.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
14
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1192-9
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:18281554-Antibodies, Monoclonal,
pubmed-meshheading:18281554-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:18281554-Antibody-Dependent Cell Cytotoxicity,
pubmed-meshheading:18281554-Antineoplastic Agents,
pubmed-meshheading:18281554-Blotting, Western,
pubmed-meshheading:18281554-Cell Line, Tumor,
pubmed-meshheading:18281554-Female,
pubmed-meshheading:18281554-Flow Cytometry,
pubmed-meshheading:18281554-Fluorescent Antibody Technique,
pubmed-meshheading:18281554-Humans,
pubmed-meshheading:18281554-Immunohistochemistry,
pubmed-meshheading:18281554-Infant,
pubmed-meshheading:18281554-Infant, Newborn,
pubmed-meshheading:18281554-Interleukin-2,
pubmed-meshheading:18281554-Leukocytes, Mononuclear,
pubmed-meshheading:18281554-Male,
pubmed-meshheading:18281554-Receptor, erbB-2,
pubmed-meshheading:18281554-Reverse Transcriptase Polymerase Chain Reaction,
pubmed-meshheading:18281554-Rhabdoid Tumor
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Trastuzumab activates allogeneic or autologous antibody-dependent cellular cytotoxicity against malignant rhabdoid tumor cells and interleukin-2 augments the cytotoxicity.
|
|
pubmed:affiliation |
Department of Pediatrics, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto, Japan. prostaff@koto.kpu-m.ac.jp
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
